Devices/Recall·openFDA/device

Life Technologies Holdings Pte Ltd — Class II: Ion Torrent Genexus Dx with software, Catalog: A40003539, which supports the Ion Torrent G

MediumPublished Oct 28, 2026· AI-analyzed Nov 2, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Life Technologies Holdings Pte Ltd has initiated a Class II recall for the Ion Torrent Genexus Dx system software (Catalog: A40003539) due to identified vulnerabilities in the DNA or RNA sequencing system software. The recall status is currently listed as ongoing.

Who it affects

This affects Life Technologies Holdings Pte Ltd, laboratory personnel utilizing the Ion Torrent Genexus Dx Integrated Sequencer, and regulatory/cybersecurity compliance officers overseeing sequencing software platforms.

Why it matters

The classification as a Class II recall indicates that the software vulnerabilities could potentially cause temporary or medically reversible adverse health consequences, though the source does not specify the exact nature of the security flaw. This highlights the increasing regulatory scrutiny on cybersecurity for integrated diagnostic platforms where software integrity is critical for accurate genomic data processing.

Practical takeaway

Regulatory and IT teams should verify the firmware and software versions of Genexus Dx systems against manufacturer remediation notices. QA should ensure that cybersecurity vulnerability assessments are integrated into the post-market surveillance process for all connected diagnostic platforms.

FDA source material

Class II. Reason: DNA or RNA sequencing system software has vulnerabilities.. Product: Ion Torrent Genexus Dx with software, Catalog: A40003539, which supports the Ion Torrent Genexus Dx Integrated Sequencer. Firm: Life Technologies Holdings Pte Ltd (Singapore Singapore). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.